StephenDJohnstonMD

PubMed

• 3 citations
  MONARCH 2: Subgroup Analysis of Patients Receiving Abemaciclib Plus Fulvestrant as First-Line and Second-Line Therapy for HR +, HER2 --Advanced Breast Cancer
  Patrick Neven, Stephen R. D. Johnston, Masakazu Toi, Joohyuk Sohn, Kenichi Inoue, Xavier Pivot, Olga Burdaeva, Meena Okera, Norikazu Masuda, Peter A. Kaufman, Han Koh,...> ;Clinical Cancer Research. 2021 Nov 1
• 7 citations
  Biomarkers of response and resistance to palbociclib plus letrozole in patients with ER+/HER2- breast cancer.
  Mitch Dowsett, Lucy Kilburn, Mothaffar F. Rimawi, C. Kent Osborne, Katherine L. Pogue-Geile, Yuan Liu, Samuel A. Jacobs, Melanie Finnigan, Shannon Puhalla, Andrew Dods...> ;Clinical Cancer Research. 2021 Oct 13
• 88 citations
  Endocrine Treatment and Targeted Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: ASCO Guideline Update.
  Harold J. Burstein, Mark R. Somerfield, Debra L. Barton, Ali Dorris, Lesley Fallowfield, Dharamvir Jain, Stephen R. D. Johnston, Larissa A. Korde, Jennifer K. Litton, ...> ;Journal of Clinical Oncology. 2021 Jul 29
• 88 citations
  Abemaciclib as initial therapy for advanced breast cancer: MONARCH 3 updated results in prognostic subgroups
  Stephen R. D. Johnston, Joyce O'Shaughnessy, Miguel Martín, Jens Huober, Masakazu Toi, Joohyuk Sohn, Valerie Andre, Holly Rene Martin, Molly C. Hardebeck, Matthew P. G...> ;NPJ Breast Cancer. 2021 Jun 22
• 3 citations
  Impact of timing of adjuvant chemothapy for early breast cancer: the Royal Marsden Hospital experience.
  Alicia Okines, Emma Kipps, T. Irfan, Maria Coakley, Vaselios Angelis, Bernice Asare, Kabir Mohammed, G. Walsh, Alistair Ring, Stephen R. D. Johnston, Marina Parton, Ni...> ;British Journal of Cancer. 2021 May 20
• 6 citations
  Cutaneous toxicities occurring during palbociclib (CDK4/6 inhibitor) and endocrine therapy in patients with advanced breast cancer: a single-centre experience
  Sumir Chawla, Alison Hill, Louise Fearfield, Stephen R. D. Johnston, Marina Parton, Kara Heelan> ;Breast Cancer Research and Treatment. 2021 Mar 8
• Reply to K. Hashimoto and A. Shimomura.
  Stephen R. D. Johnston, Nadia Harbeck, Masakazu Toi, Miguel Martin, Joyce O'Shaughnessy, Priya Rastogi> ;Journal of Clinical Oncology. 2021 Feb 25
• Reply to S. Sorscher.
  Stephen R. D. Johnston, William J Gradishar> ;Journal of Clinical Oncology. 2021 Feb 18
• 12 citations
  Meta-analyses of visceral versus non-visceral metastatic hormone receptor-positive breast cancer treated by endocrine monotherapies.
  John F.R. Robertson, Angelo Di Leo, Stephen R. D. Johnston, Stephen Chia, Judith M Bliss, Robert Paridaens, Jasmine Lichfield, Ian Bradbury, Christine M. Pierce Campbell> ;NPJ Breast Cancer. 2021 Feb 12
• 119 citations
  Final Efficacy Results of Neratinib in HER2-positive Hormone Receptor-positive Early-stage Breast Cancer From the Phase III ExteNET Trial.
  Arlene Chan, Beverly Moy, Janine Mansi, Bent Ejlertsen, Frankie A. Holmes, Stephen Chia, Hiroji Iwata, Michael Gnant, Sibylle Loibl, Carlos H. Barrios, Isil Somali, Sn...> ;Clinical Breast Cancer. 2021 Feb 1
• 31 citations
  Phase III, Randomized Study of Dual Human Epidermal Growth Factor Receptor 2 (HER2) Blockade With Lapatinib Plus Trastuzumab in Combination With an Aromatase Inhibitor...
  Stephen R D Johnston, Roberto Hegg, Seock-Ah Im, In Hae Park, Olga Burdaeva, Galina Kurteva, Michael F Press, Sergei Tjulandin, Hiroji Iwata, Sergio D Simon, Sarah Ken...> ;Journal of Clinical Oncology. 2021 Jan 1
• 3 citations
  A Prognostic Model Based on PAM50 and Clinical Variables (PAM50MET) for Metastatic Hormone Receptor-positive HER2-negative Breast Cancer.
  Aleix Prat, Yi-Hsuan Tsai, Tomás Pascual, Laia Paré, Barbara Adamo, Maria Vidal, Fara Brasó-Maristany, Patricia Galván, Jan C. Brase, Vanessa Rodrik-Outmezguine, Steph...> ;Clinical Cancer Research. 2020 Sep 22
• 365 citations
  Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2−, Node-Positive, High-Risk, Early Breast Cancer (monarchE)
  Stephen R. D. Johnston, Nadia Harbeck, Roberto Hegg, Masakazu Toi, Miguel Martín, Zhi Min Shao, Q. Zhang, Jorge Luis Martinez Rodriguez, Mario Campone, Erika Hamilton,...> ;Journal of Clinical Oncology. 2020 Sep 20
• 27 citations
  Health-Related Quality of Life in MONARCH 3: Abemaciclib plus an Aromatase Inhibitor as Initial Therapy in HR+, HER2- Advanced Breast Cancer.
  Matthew P. Goetz, Miguel Martin, Eriko Tokunaga, In Hae Park, Jens Huober, Masakazu Toi, Clemens Stoffregen, Sarah Shekarriz, Valerie Andre, M. Corona Gainford, Gregor...> ;The Oncologist. 2020 Sep 1
• 63 citations
  ESR1 Mutations and Overall Survival on Fulvestrant versus Exemestane in Advanced Hormone Receptor–Positive Breast Cancer: A Combined Analysis of the Phase III SoFEA an...
  Nicholas C. Turner, Claire Swift, Lucy Kilburn, Charlotte Fribbens, Matthew Beaney, Isaac Garcia-Murillas, Aman U. Budzar, John F.R. Robertson, William J. Gradishar, M...> ;Clinical Cancer Research. 2020 Jun 16
• 120 citations
  Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive a...
  Sara M. Tolaney, Andrew M Wardley, Stefania Zambelli, John Hilton, Tiffany A. Troso-Sandoval, Francesco Ricci, Seock-Ah Im, Sung Bae Kim, Stephen R. D. Johnston, Arlen...> ;The Lancet. Oncology. 2020 Jun 1
• 43 citations
  Tumour kinome re-wiring governs resistance to palbociclib in oestrogen receptor positive breast cancers, highlighting new therapeutic modalities.
  Sunil Pancholi, Ricardo Ribas, Nikiana Simigdala, Eugene Schuster, Joanna Nikitorowicz-Buniak, Anna Ressa, Qiong Gao, Mariana Ferreira Leal, Amandeep Bhamra, Allan Tho...> ;Oncogene. 2020 Apr 19
• 50 citations
  Inactivating NF1 Mutations Are Enriched in Advanced Breast Cancer and Contribute to Endocrine Therapy Resistance.
  Alex Pearson, Paula Proszek, Javier Pascual, Charlotte Fribbens, Monee K Shamsher, Belinda Kingston, Ben O'Leary, Maria Teresa Herrera-Abreu, Rosalind J. Cutts, Isaac ...> ;Clinical Cancer Research. 2020 Feb 1
• Correction to: Combination of mTORC1/2 inhibitor vistusertib plus fulvestrant in vitro and in vivo targets oestrogen receptor-positive endocrine-resistant breast cancer.
  Sunil Pancholi, Mariana Ferreira Leal, Ricardo Ribas, Nikiana Simigdala, Eugene Schuster, Sophie Chateau-Joubert, Lila Zabaglo, Margaret Hills, Andrew Dodson, Qiong Ga...> ;Breast Cancer Research. 2020 Jan 31
• 15 citations
  Pathological complete response to neoadjuvant systemic therapy in 789 early and locally advanced breast cancer patients: The Royal Marsden experience
  Nicolò Matteo Luca Battisti, Victoria True, Narda Chaabouni, Neha Chopra, Karla A. Lee, Scott Shepherd, Tal Shapira-Rotenberg, Rashi Joshi, Sophie McGrath, Alicia Okin...> ;Breast Cancer Research and Treatment. 2020 Jan 1
• 4 citations
  Evidence-based guidelines for managing patients with primary ER+ HER2- breast cancer deferred from surgery due to the COVID-19 pandemic.
  Mitch Dowsett, Matthew J Ellis, J Michael Dixon, Oleg Gluz, John Robertson, Ronald Kates, Vera J Suman, Arran K Turnbull, Ulrike Nitz, Matthias Christgen, Hans Kreipe,...> ;NPJ Breast Cancer. 2020 Jan 1
• 14 citations
  Safety and efficacy of T-DM1 in patients with advanced HER2-positive breast cancer The Royal Marsden experience
  Nicolò Matteo Luca Battisti, Frances Rogerson, Karla A. Lee, Scott Shepherd, Kabir Mohammed, Nicholas C. Turner, Sophie McGrath, Alicia Okines, Marina Parton, Stephen ...> ;Cancer Treatment and Research Communications. 2020 Jan 1
• 481 citations
  The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy-MONARCH ...
  George W. Sledge, Masakazu Toi, Patrick Neven, Joohyuk Sohn, Kenichi Inoue, Xavier Pivot, Olga Burdaeva, Meena Okera, Norikazu Masuda, Peter A. Kaufman, Han Koh, EM Gr...> ;JAMA Oncology. 2020 Jan 1
• 8 citations
  Combination of mTORC1/2 inhibitor vistusertib plus fulvestrant in vitro and in vivo targets oestrogen receptor-positive endocrine-resistant breast cancer.
  Sunil Pancholi, Mariana Ferreira Leal, Ricardo Ribas, Nikiana Simigdala, Eugene Schuster, Sophie Chateau-Joubert, Lila Zabaglo, Margaret Hills, Andrew Dodson, Qiong Ga...> ;Breast Cancer Research. 2019 Dec 4
• 203 citations
  Assessment of Molecular Relapse Detection in Early-Stage Breast Cancer.
  Isaac Garcia-Murillas, Neha Chopra, Iñaki Comino-Mendez, Matthew Beaney, Holly Tovey, Rosalind J. Cutts, Claire Swift, Divya Kriplani, M Afentakis, Sarah Hrebien, Gise...> ;JAMA Oncology. 2019 Oct 1
• Join now to see all